Osteosarcoma-Pipeline Review, H1 2016

Osteosarcoma-Pipeline Review, H1 2016


  • Products Id :- GMDHC7808IDB
  • |
  • Pages: 306
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Global Markets Direct's, 'Osteosarcoma-Pipeline Review, H1 2016', provides an overview of the Osteosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Osteosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Osteosarcoma

The report reviews pipeline therapeutics for Osteosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Osteosarcoma therapeutics and enlists all their major and minor projects

The report assesses Osteosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Osteosarcoma

Reasons To Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Osteosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Osteosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Osteosarcoma Overview 9

Therapeutics Development 10

Pipeline Products for Osteosarcoma-Overview 10

Pipeline Products for Osteosarcoma-Comparative Analysis 11

Osteosarcoma-Therapeutics under Development by Companies 12

Osteosarcoma-Therapeutics under Investigation by Universities/Institutes 15

Osteosarcoma-Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Osteosarcoma-Products under Development by Companies 18

Osteosarcoma-Products under Investigation by Universities/Institutes 21

Osteosarcoma-Companies Involved in Therapeutics Development 22

Advaxis, Inc. 22

Amgen Inc. 23

Astellas Pharma Inc. 24

AVEO Pharmaceuticals, Inc. 25

Bayer AG 26

Bellicum Pharmaceuticals, Inc. 27

Cebiotex, S.L. 28

Celgene Corporation 29

Celldex Therapeutics, Inc. 30

CytRx Corporation 31

Eleison Pharmaceuticals LLC 32

EntreChem, S.L. 33

Exelixis, Inc. 34

Gradalis Inc. 35

Ipsen S.A. 36

Isofol Medical AB 37

Karyopharm Therapeutics, Inc. 38

Kolltan Pharmaceuticals, Inc. 39

MediaPharma s.r.l. 40

Merck & Co., Inc. 41

Merrimack Pharmaceuticals, Inc. 42

NanoSmart Pharmaceuticals, Inc. 43

Nanovalent Pharmaceuticals Inc. 44

NantKwest, Inc. 45

Netris Pharma S.A.S. 46

Novartis AG 47

Oncolys BioPharma Inc. 48

Oncomatryx Biopharma, S.L. 49

Recombio S.L 50

Shionogi & Co., Ltd. 51

Sigma-Tau S.p.A. 52

Sutro Biopharma, Inc. 53

Teijin Pharma Limited 54

Tesaro, Inc. 55

Tokalas, Inc. 56

United Therapeutics Corporation 57

Osteosarcoma-Therapeutics Assessment 58

Assessment by Monotherapy Products 58

Assessment by Target 59

Assessment by Mechanism of Action 63

Assessment by Route of Administration 66

Assessment by Molecule Type 68

Drug Profiles 70

2-GES-Drug Profile 70

3BP-227-Drug Profile 71

3D-QM-Drug Profile 72

3D-QMS-Drug Profile 73

ADXS-HER2-Drug Profile 74

aldoxorubicin hydrochloride-Drug Profile 76

AM-7209-Drug Profile 79

AU-101-Drug Profile 80

AU-105-Drug Profile 81

AV-203-Drug Profile 82

cabozantinib s-malate-Drug Profile 83

CEB-01-Drug Profile 87

Cellular Immunotherapy for GD2 Expressing Solid Tumors-Drug Profile 88

Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma-Drug Profile 89

Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 90

celyvir-Drug Profile 91

CGS-200-Drug Profile 93

cisplatin SR-Drug Profile 94

dactinomycin next generation-Drug Profile 96

dinutuximab-Drug Profile 97

Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma-Drug Profile 99

EC-8042-Drug Profile 100

EC-8105-Drug Profile 102

everolimus-Drug Profile 103

gemogenovatucel-T-Drug Profile 109

glembatumumab vedotin-Drug Profile 111

haNK Program-Drug Profile 113

irinotecan hydrochloride-Drug Profile 115

KIT-SG3227-Drug Profile 118

ligerin-Drug Profile 120

linsitinib-Drug Profile 121

LLL-12-Drug Profile 123

Modufolin-Drug Profile 124

Monoclonal Antibody Conjugate for Ewing Sarcoma-Drug Profile 126

Monoclonal Antibody for Osteosarcoma-Drug Profile 127

Monoclonal Antibody to Inhibit GD2 for Oncology-Drug Profile 128

Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma-Drug Profile 129

Monoclonal Antibody to Target GD2 for Osteosarcoma-Drug Profile 131

MPE-8.3-Drug Profile 132

niraparib-Drug Profile 133

NP-137-Drug Profile 135

NV-101-Drug Profile 137

OBP-702-Drug Profile 138

Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer-Drug Profile 139

OMTX-503-Drug Profile 140

OMTX-703-Drug Profile 141

paclitaxel albumin bound-Drug Profile 142

pazopanib hydrochloride-Drug Profile 146

pembrolizumab-Drug Profile 152

Peptide to Target COX-2 and MAS-GPCR for Oncology-Drug Profile 162

racotumomab-Drug Profile 164

radium Ra 223 dichloride-Drug Profile 166

roneparstat-Drug Profile 169

RSF-101-Drug Profile 170

S-588410-Drug Profile 171

selinexor-Drug Profile 172

SEN-461-Drug Profile 178

Small Molecules for Ewing Sarcoma-Drug Profile 179

Small Molecules to Agonize Vitamin D3 Receptor for Osteosarcoma-Drug Profile 180

Small Molecules to Inhibit CaMKII for Osteosarcoma-Drug Profile 181

SP-2509-Drug Profile 182

SP-2528-Drug Profile 184

SP-2577-Drug Profile 185

ST-3595-Drug Profile 186

T-2GES-Drug Profile 187

TK-216-Drug Profile 188

Vaccine for Osteosarcoma-Drug Profile 189

YK-4279-Drug Profile 190

Osteosarcoma-Recent Pipeline Updates 192

Osteosarcoma-Dormant Projects 290

Osteosarcoma-Discontinued Products 293

Osteosarcoma-Product Development Milestones 294

Featured News & Press Releases 294

Appendix 300

Methodology 300

Coverage 300

Secondary Research 300

Primary Research 300

Expert Panel Validation 300

Contact Us 300

Disclaimer 301

List of Figures

Number of Products under Development for Osteosarcoma, H1 2016 15

Number of Products under Development for Osteosarcoma-Comparative Analysis, H1 2016 16

Number of Products under Development by Companies, H1 2016 17

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Clinical Stage Development, H1 2016 21

Comparative Analysis by Early Stage Products, H1 2016 22

Assessment by Monotherapy Products, H1 2016 63

Number of Products by Top 10 Targets, H1 2016 64

Number of Products by Stage and Top 10 Targets, H1 2016 64

Number of Products by Top 10 Mechanism of Actions, H1 2016 68

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 68

Number of Products by Top 10 Routes of Administration, H1 2016 71

Number of Products by Stage and Top 10 Routes of Administration, H1 2016 71

Number of Products by Top 10 Molecule Types, H1 2016 73

Number of Products by Stage and Top 10 Molecule Types, H1 2016 73

List of Tables

Number of Products under Development for Osteosarcoma, H1 2016 15

Number of Products under Development for Osteosarcoma-Comparative Analysis, H1 2016 16

Number of Products under Development by Companies, H1 2016 17

Number of Products under Development by Companies, H1 2016 (Contd..1) 18

Number of Products under Development by Companies, H1 2016 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2016 20

Comparative Analysis by Clinical Stage Development, H1 2016 21

Comparative Analysis by Early Stage Development, H1 2016 22

Products under Development by Companies, H1 2016 23

Products under Development by Companies, H1 2016 (Contd..1) 24

Products under Development by Companies, H1 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H1 2016 26

Osteosarcoma-Pipeline by Advaxis, Inc., H1 2016 27

Osteosarcoma-Pipeline by Amgen Inc., H1 2016 28

Osteosarcoma-Pipeline by Astellas Pharma Inc., H1 2016 29

Osteosarcoma-Pipeline by AVEO Pharmaceuticals, Inc., H1 2016 30

Osteosarcoma-Pipeline by Bayer AG, H1 2016 31

Osteosarcoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2016 32

Osteosarcoma-Pipeline by Cebiotex, S.L., H1 2016 33

Osteosarcoma-Pipeline by Celgene Corporation, H1 2016 34

Osteosarcoma-Pipeline by Celldex Therapeutics, Inc., H1 2016 35

Osteosarcoma-Pipeline by CytRx Corporation, H1 2016 36

Osteosarcoma-Pipeline by Eleison Pharmaceuticals LLC, H1 2016 37

Osteosarcoma-Pipeline by EntreChem, S.L., H1 2016 38

Osteosarcoma-Pipeline by Exelixis, Inc., H1 2016 39

Osteosarcoma-Pipeline by Gradalis Inc., H1 2016 40

Osteosarcoma-Pipeline by Ipsen S.A., H1 2016 41

Osteosarcoma-Pipeline by Isofol Medical AB, H1 2016 42

Osteosarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2016 43

Osteosarcoma-Pipeline by Kolltan Pharmaceuticals, Inc., H1 2016 44

Osteosarcoma-Pipeline by MediaPharma s.r.l., H1 2016 45

Osteosarcoma-Pipeline by Merck & Co., Inc., H1 2016 46

Osteosarcoma-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 47

Osteosarcoma-Pipeline by NanoSmart Pharmaceuticals, Inc., H1 2016 48

Osteosarcoma-Pipeline by Nanovalent Pharmaceuticals Inc., H1 2016 49

Osteosarcoma-Pipeline by NantKwest, Inc., H1 2016 50

Osteosarcoma-Pipeline by Netris Pharma S.A.S., H1 2016 51

Osteosarcoma-Pipeline by Novartis AG, H1 2016 52

Osteosarcoma-Pipeline by Oncolys BioPharma Inc., H1 2016 53

Osteosarcoma-Pipeline by Oncomatryx Biopharma, S.L., H1 2016 54

Osteosarcoma-Pipeline by Recombio S.L, H1 2016 55

Osteosarcoma-Pipeline by Shionogi & Co., Ltd., H1 2016 56

Osteosarcoma-Pipeline by Sigma-Tau S.p.A., H1 2016 57

Osteosarcoma-Pipeline by Sutro Biopharma, Inc., H1 2016 58

Osteosarcoma-Pipeline by Teijin Pharma Limited, H1 2016 59

Osteosarcoma-Pipeline by Tesaro, Inc., H1 2016 60

Osteosarcoma-Pipeline by Tokalas, Inc., H1 2016 61

Osteosarcoma-Pipeline by United Therapeutics Corporation, H1 2016 62

Assessment by Monotherapy Products, H1 2016 63

Number of Products by Stage and Target, H1 2016 65

Number of Products by Stage and Mechanism of Action, H1 2016 69

Number of Products by Stage and Route of Administration, H1 2016 72

Number of Products by Stage and Molecule Type, H1 2016 74

Osteosarcoma Therapeutics-Recent Pipeline Updates, H1 2016 197

Osteosarcoma-Dormant Projects, H1 2016 295

Osteosarcoma-Dormant Projects (Contd..1), H1 2016 296

Osteosarcoma-Dormant Projects (Contd..2), H1 2016 297

Osteosarcoma-Discontinued Products, H1 2016 298

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Advaxis, Inc.

Amgen Inc.

Astellas Pharma Inc.

AVEO Pharmaceuticals, Inc.

Bayer AG

Bellicum Pharmaceuticals, Inc.

Cebiotex, S.L.

Celgene Corporation

Celldex Therapeutics, Inc.

CytRx Corporation

Eleison Pharmaceuticals LLC

EntreChem, S.L.

Exelixis, Inc.

Gradalis Inc.

Ipsen S.A.

Isofol Medical AB

Karyopharm Therapeutics, Inc.

Kolltan Pharmaceuticals, Inc.

MediaPharma s.r.l.

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

NanoSmart Pharmaceuticals, Inc.

Nanovalent Pharmaceuticals Inc.

NantKwest, Inc.

Netris Pharma S.A.S.

Novartis AG

Oncolys BioPharma Inc.

Oncomatryx Biopharma, S.L.

Recombio S.L

Shionogi & Co., Ltd.

Sigma-Tau S.p.A.

Sutro Biopharma, Inc.

Teijin Pharma Limited

Tesaro, Inc.

Tokalas, Inc.

United Therapeutics Corporation

Osteosarcoma Therapeutic Products under Development, Key Players in Osteosarcoma Therapeutics, Osteosarcoma Pipeline Overview, Osteosarcoma Pipeline, Osteosarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 129160
Site License
USD 4000 INR 258320
Corporate User License
USD 6000 INR 387480

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com